


Ascletis presented at the 26th APASL annual meeting and held successfully “China-Developed DAAs, Eliminating HCV in China by 2030” symposium

The 26th Conference of Asian Pacific Association for the Study of the Liver (APASL) was held at the Shanghai International Convention Centre from 15 to 19 February, 2017. This is the second time for China to host the APASL annual meeting since seven years ago. Being one of the largest annual events in the field, APASL 2017 attracted hepatology experts and physicians from all over the world. Ascletis stands out as the leading domestic company in HCV treatment by the latest R&D progress on its HCV new drugs. Ascletis’ effort and progress has attracted the experts’ attention and gained their recognition.



Two clinical trials sponsored by Ascletis were accepted as late breaker oral presentation by APASL 2017: one is MAKALU study of Danoprevir plus PR triple therapy; the other one is EVEREST study of the all-oral therapy with Danoprevir in combination with Ravidasvir. MAKALU study was presented by Professor Lai Wei; EVEREST study was presented by Professor Ming-Lung Yu (Kaohsiung). The data of the MAKALU study reveals that the 12-week treatment with the triple therapy of Danoprevir in combination with PR produced 96% SVR12 in HCV Genotype 1 Chinese patients, with no virologic breakthrough during the treatment; the data of the EVEREST study indicates that the 12-week treatment with the all-oral therapy of Danoprevir in combination with Ravidasvir produced 100% SVR12 and SVR24, and 100% SVR was achieved in patients with baseline NS5A resistance-associated variants.

“China-Developed DAAs, Eliminating HCV in China by 2030” symposium was successfully held by Ascletis from 17:30 to 19:00 on 18th February. Academician Lanjuan Li, Academician Fusheng Wang, Professor Jinlin Hou (Chairman, APASL 2017), Professor Zhongping Duan (present Chairman, Chinese Society of Hepatology, CMA) co-chaired the symposium and Professor

Guiqiang Wang (present Chairman, Society for Infectious Diseases, CMA), Professor Qing Xie (present Vice Chairman, Society for Infectious Diseases, CMA), as well as Professor Lai Wei and Professor Ming-Lung Yu (Kaohsiung), two principle investigators of the Ascletis' clinical trials, gave the keynote speech at the symposium. More than 500 domestic and international professionals attended the symposium.



Four speakers systematically conveyed the China's forthcoming strategies to eliminate HCV and its action plan; they also presented the progress in the clinical trials of the two China developed DAAs (Danoprevir and Ravidasvir). All the chairperson and speakers affirmed the excellent safety profiles and efficacy of Danoprevir and Ravidasvir; they strongly supported the DAAs' launch in China and expected China-developed DAAs to play a significant role in the treatment and prevention of HCV in the country. Academician Lanjuan Li concluded with the remarks: "As the first achievement supported by the National Major Scientific and Technological Special Project for Significant New Drugs Development during the 13th Five-Year Plan Period, the early launch of China-developed DAA - Danoprevir will better meet the tens of millions of Chinese HCV patients' clinical needs, effectively reduce the economic burden of both the patients and our country, help resolve major public health issue, and challenge the MNCs' dominant status in technology and markets. Just like how the high speed "Harmony Express" improved the lives of Chinese, Ascletis will make a technological breakthrough in the field of the China new drug development. "



The Ascletis booth, decorated in traditional Chinese style, were visited by more than 1500 attendees in two and half days.

A number of professional media, such as Professional media, Hepatology Digest and HepC Online reported this symposium.